Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis

References

• Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413–431.
   PubMed Web of Science ®Google Scholar
• Barlev N, Sayan B, Candi E, et al. The microRNA and p53 families join forces against cancer. Cell Death Differ. 2010;17(2):373.
   PubMed Web of Science ®Google Scholar
• Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol. 2010;2(8):a000935.
   PubMed Web of Science ®Google Scholar
• Grossi E, Sánchez Y, Huarte M. Expanding the p53 regulatory network: lncRNAs take up the challenge. Biochimica Et Biophysica Acta (Bba)-Gene Regulatory Mechanisms. 2016;1859(1):200–208.
   PubMed Web of Science ®Google Scholar
• Lezina L, Purmessur N, Antonov A, et al. miR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress. Cell Death Dis. 2013;4(12):e953.
   PubMedGoogle Scholar
• Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299–303.
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237–1245.
   PubMed Web of Science ®Google Scholar
• Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. 1993.
   Google Scholar
• Shvarts A, Steegenga W, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996;15(19):5349.
   PubMed Web of Science ®Google Scholar
• Stad R, Little NA, Xirodimas DP, et al. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Reports. 2001;2(11):1029–1034.
   PubMed Web of Science ®Google Scholar
• Barak Y, Juven T, Haffner R, et al. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993;12(2):461.
   PubMed Web of Science ®Google Scholar
• Wu X, Bayle JH, Olson D, et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7(7a):1126–1132.
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes therapid degradation of p53. Nature. 1997;387(6630):296–299.
   PubMed Web of Science ®Google Scholar
• Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996;274(5289):948.
   PubMed Web of Science ®Google Scholar
• Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol. 1993;13(7):4107–4114.
   PubMed Web of Science ®Google Scholar
• Argentini M, Barboule N, Wasylyk B. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene. 2001;20(11):1267–1275.
   PubMed Web of Science ®Google Scholar
• Blattner C, Hay T, Meek DW, et al. Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol. 2002;22(17):6170–6182.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Yao J, Wani G, et al. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53 EVIDENCE FOR THE ROLE OF p300 In Integrating Ubiquitination and Proteolysis. J Biol Chem. 2001;276(32):29695–29701.
   PubMed Web of Science ®Google Scholar
• Kulikov R, Winter M, Blattner C. Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem. 2006;281(39):28575–28583.
   PubMed Web of Science ®Google Scholar
• Chène P. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy. Nature Rev Cancer. 2003;3(2):102–109.
   PubMed Web of Science ®Google Scholar
• Wade M, Li Y-C, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13(2):83–96.
   PubMed Web of Science ®Google Scholar
• Haitel A, Wiener HG, Baethge U, et al. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res. 2000;6(5):1840–1844.
   PubMed Web of Science ®Google Scholar
• Rayburn E, Zhang R, He J, et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005;5(1):27–41.
   PubMed Web of Science ®Google Scholar
• Marouco D, Garabadgiu AV, Melino G, et al. Lysine-specific modifications of p53: a matter of life and death? Oncotarget. 2013;4(10):1556.
   PubMedGoogle Scholar
• Sakaguchi K, Herrera JE, Saito S, et al. DNA damage activates p53 through a phosphorylation–acetylation cascade. Genes Dev. 1998;12(18):2831–2841.
   PubMed Web of Science ®Google Scholar
• Lezina L, Aksenova V, Fedorova O, et al. KMT set7/9 affects genotoxic stress response via the Mdm2 axis. Oncotarget. 2015;6(28):25843.
   PubMedGoogle Scholar
• Morgunkova A, Barlev NA. Lysine methylation goes global. Cell Cycle. 2006;5(12):1308–1312.
   PubMed Web of Science ®Google Scholar
• Barlev NA, Liu L, Chehab NH, et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell. 2001;8(6):1243–1254.
   PubMed Web of Science ®Google Scholar
• Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell. 2001;8(1):57–69.
   PubMed Web of Science ®Google Scholar
• Ivanov GS, Ivanova T, Kurash J, et al. Methylation-acetylation interplay activates p53 in response to DNA damage. Mol Cell Biol. 2007;27(19):6756–6769.
   PubMed Web of Science ®Google Scholar
• Ding Q, Zhang Z, J-J L, et al. Discovery of RG7388, a potent and selective p53–MDM2 inhibitor in clinical development. J Med Chem. 2013;56(14):5979–5983.
   PubMed Web of Science ®Google Scholar
• Saha MN, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013;6(1):1.
   PubMedGoogle Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844–848.
   PubMed Web of Science ®Google Scholar
• Reed D, Shen Y, Shelat AA, et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem. 2010;285(14):10786–10796.
   PubMed Web of Science ®Google Scholar
• Chang YS, Graves B, Guerlavais V, et al. Stapled α− helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci. 2013;110(36):E3445–E3454.
   PubMed Web of Science ®Google Scholar
• Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008;14(17):5318–5324.
   PubMed Web of Science ®Google Scholar
• Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells. Cancer Sci. 2011;102(3):605–613.
   PubMed Web of Science ®Google Scholar
• Tabe Y, Sebasigari D, Jin L, et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009;15(3):933–942.
   PubMed Web of Science ®Google Scholar
• Zhang B, Golding BT, Hardcastle IR. Small-molecule MDM2-p53 inhibitors: recent advances. Future Med Chem. 2015;7(5):631–645.
   PubMed Web of Science ®Google Scholar
• Hu B, Gilkes DM, Farooqi B, et al. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem. 2006;281(44):33030–33035.
   PubMed Web of Science ®Google Scholar
• Michaelis M, Rothweiler F, Klassert D, et al. Reversal of P-glycoprotein–mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res. 2009;69(2):416–421.
   PubMed Web of Science ®Google Scholar
• Davidovich P, Aksenova V, Petrova V, et al. Discovery of novel isatin-based p53 inducers. ACS Med Chem Lett. 2015;6(8):856–860.
   PubMed Web of Science ®Google Scholar
• Rana S, Blowers EC, Tebbe C, et al. Isatin derived spirocyclic analogues with α-methylene-γ-butyrolactone as anticancer agents: a structure–activity relationship study. J Med Chem. 2016;59(10):5121–5127.
   PubMed Web of Science ®Google Scholar
• Evdokimov NM, Magedov IV, McBrayer D, et al. Isatin derivatives with activity against apoptosis-resistant cancer cells. Bioorg Med Chem Lett. 2016;26(6):1558–1560.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Ko K-W, Choe Y-J, et al. Nutlin-3, a MDM2 antagonist, induces Erk1/2 activation in U2OS cells. FASEB J. 2010;24(1 Supplement):485.16–485.16.
   Google Scholar
• Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle. 2004;3(4):417–419.
   Web of Science ®Google Scholar
• Fedorova OA, Moiseeva TN, Nikiforov AA, et al. Proteomic analysis of the 20S proteasome (PSMA3)-interacting proteins reveals a functional link between the proteasome and mRNA metabolism. Biochem Biophys Res Commun. 2011;416(3):258–265.
   PubMed Web of Science ®Google Scholar
• Moiseeva TN, Bottrill A, Melino G, et al. DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity. Oncotarget. 2013;4(9):1338–1348.
   PubMedGoogle Scholar
• Allen MA, Andrysik Z, Dengler VL, et al. Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. Elife. 2014;3:e02200.
   PubMed Web of Science ®Google Scholar
• Ha J-H, Won E-Y, Shin J-S, et al. Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins. J Am Chem Soc. 2011;133(5):1244–1247.
   PubMed Web of Science ®Google Scholar
• Shin J-S, Ha J-H, He F, et al. Structural insights into the dual-targeting mechanism of Nutlin-3. Biochem Biophys Res Commun. 2012;420(1):48–53.
   PubMed Web of Science ®Google Scholar
• Yu B, Yu Z, Qi P-P, et al. Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: success and challenges. Eur J Med Chem. 2015;95:35–40.
   PubMed Web of Science ®Google Scholar
• Lauriola L, Granone P, Ramella S, et al. Expression of the RNA-binding protein HuR and its clinical significance in human stage I and II lung adenocarcinoma. Histol Histopathol. 2012;27(5):617–626.
   PubMed Web of Science ®Google Scholar